Australian Progen CEO Says Oncology Pipeline Advances Despite Troubles
This article was originally published in PharmAsia News
Executive Summary
Australia's Progen Pharmaceuticals says it is staying on track and pushing its anti-cancer drugs through its pipeline despite several upheavals that have plagued it for the past six months. CEO Justus Homburg presented an upbeat view of the company's prospects, such as its metastatic melanoma drug now about to enter Phase II trials. Progen also says its small-molecule heparanese inhibitor discovery program also is getting encouraging results. Progen has been under attack by two separate groups of shareholders, including another cancer drug developer with stock, Cytopia, which also helped derail a Progen merger with Avexa. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.